Literature DB >> 22923501

Resveratrol sensitizes acute myelogenous leukemia cells to histone deacetylase inhibitors through reactive oxygen species-mediated activation of the extrinsic apoptotic pathway.

Alae Yaseen1, Shuang Chen, Stefanie Hock, Roberto Rosato, Paul Dent, Yun Dai, Steven Grant.   

Abstract

Histone deacetylase inhibitors (HDACIs) activate the prosurvival nuclear factor-κB (NF-κB) pathway by hyperacetylating RelA/p65, whereas the chemopreventive agent resveratrol inhibits NF-κB by activating the class III histone deacetylase Sirt1. Interactions between resveratrol and pan-HDACIs (vorinostat and panobinostat) were examined in human acute myelogenous leukemia (AML) cells. Pharmacologically achievable resveratrol concentrations (25-50 μM) synergistically potentiated HDACI lethality in AML cell lines and primary AML blasts. Resveratrol antagonized RelA acetylation and NF-κB activation in HDACI-treated cells. However, short hairpin RNA Sirt1 knockdown failed to modify HDACI sensitivity, which suggests that factors other than or in addition to Sirt1 activation contribute to resveratrol/HDACI interactions. These interactions were associated with death receptor 5 (DR5) up-regulation and caspase-8 activation, whereas cells expressing dominant-negative caspase-8 were substantially protected from resveratrol/HDACI treatment, which suggests a significant functional role for the extrinsic apoptotic pathway in lethality. Exposure to resveratrol with HDACI induced sustained reactive oxygen species (ROS) generation, which was accompanied by increased levels of DNA double-strand breaks, as reflected in γH2A.X and comet assays. The free radical scavenger Mn(III)tetrakis(4-benzoic acid)porphyrin chloride blocked ROS generation, DR5 up-regulation, caspase-8 activation, DNA damage, and apoptosis, which indicates a primary role for oxidative injury in lethality. Analyses of cell-cycle progression and 5-ethynyl-2'-deoxyuridine incorporation through flow cytometry revealed that resveratrol induced S-phase accumulation; this effect was abrogated by HDACI coadministration, which suggests that cells undergoing DNA synthesis may be particularly vulnerable to HDACI lethality. Collectively, these findings indicate that resveratrol interacts synergistically with HDACIs in AML cells through multiple ROS-dependent actions, including death receptor up-regulation, extrinsic apoptotic pathway activation, and DNA damage induction. They also raise the possibility that S-phase cells may be particularly susceptible to these actions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22923501      PMCID: PMC3502626          DOI: 10.1124/mol.112.079624

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  56 in total

1.  Nitric oxide inhibits apoptosis by preventing increases in caspase-3-like activity via two distinct mechanisms.

Authors:  Y M Kim; R V Talanian; T R Billiar
Journal:  J Biol Chem       Date:  1997-12-05       Impact factor: 5.157

2.  Catalase catalyzes nitrotyrosine formation from sodium azide and hydrogen peroxide.

Authors:  K Ogino; N Kodama; M Nakajima; A Yamada; H Nakamura; H Nagase; D Sadamitsu; T Maekawa
Journal:  Free Radic Res       Date:  2001-12

3.  Resveratrol causes arrest in the S-phase prior to Fas-independent apoptosis in CEM-C7H2 acute leukemia cells.

Authors:  D Bernhard; I Tinhofer; M Tonko; H Hübl; M J Ausserlechner; R Greil; R Kofler; A Csordas
Journal:  Cell Death Differ       Date:  2000-09       Impact factor: 15.828

4.  Chemopreventive properties of trans-resveratrol are associated with inhibition of activation of the IkappaB kinase.

Authors:  M Holmes-McNary; A S Baldwin
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

5.  Duration of nuclear NF-kappaB action regulated by reversible acetylation.

Authors:  W Fischle; E Verdin; W C Greene
Journal:  Science       Date:  2001-08-31       Impact factor: 47.728

6.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species.

Authors:  A A Ruefli; M J Ausserlechner; D Bernhard; V R Sutton; K M Tainton; R Kofler; M J Smyth; R W Johnstone
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-04       Impact factor: 11.205

7.  Two CD95 (APO-1/Fas) signaling pathways.

Authors:  C Scaffidi; S Fulda; A Srinivasan; C Friesen; F Li; K J Tomaselli; K M Debatin; P H Krammer; M E Peter
Journal:  EMBO J       Date:  1998-03-16       Impact factor: 11.598

Review 8.  Anti-leukemia effect of resveratrol.

Authors:  Min-Fu Tsan; Julie E White; Jewraj G Maheshwari; G Chikkappa
Journal:  Leuk Lymphoma       Date:  2002-05

9.  The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

Authors:  Sonia C Maggio; Roberto R Rosato; Lora B Kramer; Yun Dai; Mohamed Rahmani; David S Paik; Ann C Czarnik; Shawn G Payne; Sarah Spiegel; Steven Grant
Journal:  Cancer Res       Date:  2004-04-01       Impact factor: 12.701

10.  Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase.

Authors:  Fan Yeung; Jamie E Hoberg; Catherine S Ramsey; Michael D Keller; David R Jones; Roy A Frye; Marty W Mayo
Journal:  EMBO J       Date:  2004-05-20       Impact factor: 11.598

View more
  18 in total

1.  Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.

Authors:  Nilsa Rivera-Del Valle; Tiewei Cheng; Mary E Irwin; Hayley Donnella; Melissa M Singh; Joya Chandra
Journal:  Cancer Chemother Pharmacol       Date:  2018-01-08       Impact factor: 3.333

Review 2.  Small molecule inhibitors in acute myeloid leukemia: from the bench to the clinic.

Authors:  Muneera Al-Hussaini; John F DiPersio
Journal:  Expert Rev Hematol       Date:  2014-08       Impact factor: 2.929

Review 3.  Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights.

Authors:  Prithviraj Bose; Yun Dai; Steven Grant
Journal:  Pharmacol Ther       Date:  2014-04-24       Impact factor: 12.310

4.  Reverse chemomodulatory effects of the SIRT1 activators resveratrol and SRT1720 in Ewing's sarcoma cells: resveratrol suppresses and SRT1720 enhances etoposide- and vincristine-induced anticancer activity.

Authors:  Jürgen Sonnemann; Melanie Kahl; Priyanka M Siranjeevi; Annelie Blumrich; Lisa Blümel; Sabine Becker; Susan Wittig; René Winkler; Oliver H Krämer; James F Beck
Journal:  J Cancer Res Clin Oncol       Date:  2015-06-09       Impact factor: 4.553

Review 5.  Histone deacetylase inhibitors and cell death.

Authors:  Jing Zhang; Qing Zhong
Journal:  Cell Mol Life Sci       Date:  2014-06-05       Impact factor: 9.261

6.  Inhibition of autophagy significantly enhances combination therapy with sorafenib and HDAC inhibitors for human hepatoma cells.

Authors:  Hang Yuan; Ai-Jun Li; Sen-Lin Ma; Long-Jiu Cui; Bin Wu; Lei Yin; Meng-Chao Wu
Journal:  World J Gastroenterol       Date:  2014-05-07       Impact factor: 5.742

Review 7.  The Anti-Leukemic Activity of Natural Compounds.

Authors:  Coralia Cotoraci; Alina Ciceu; Alciona Sasu; Eftimie Miutescu; Anca Hermenean
Journal:  Molecules       Date:  2021-05-05       Impact factor: 4.411

8.  Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells.

Authors:  Mo-Li Wu; Hong Li; Li-Jun Yu; Xiao-Yan Chen; Qing-You Kong; Xue Song; Xiao-Hong Shu; Jia Liu
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

9.  Antioxidants impair anti-tumoral effects of Vorinostat, but not anti-neoplastic effects of Vorinostat and caspase-8 downregulation.

Authors:  Laura Bergadà; Andree Yeramian; Annabel Sorolla; Xavier Matias-Guiu; Xavier Dolcet
Journal:  PLoS One       Date:  2014-03-20       Impact factor: 3.240

Review 10.  Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia.

Authors:  Fang-Liang Huang; Sheng-Jie Yu; Chia-Ling Li
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.